The global liquid biopsy market size is expected to reach USD 5.96 billion by 2030, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 13.4% during the forecast period. Enhanced view of tumor provided by liquid biopsy technology is estimated to augment the market in coming years.
While tissue biopsies have been standard for cancer diagnosis for past several year, their highly invasive nature and frequently associated complications have been major concerns. Moreover, these biopsies lead to high expenditure being incurred by patients. Liquid biopsies, on the other hand, offer a less invasive methodology along with high effectiveness. Thus, there are a number of key private organizations involved in rigorous R&D activities for liquid biopsy test development and it is only a matter of time before these procedures grow in prominence in diagnostic paraphernalia of oncologists and pathologists.
Technological developments such as electric field induced release and measurement (EFIRM)- Liquid Biopsy (eLB), which provides detection that can assist clinical treatment decisions for most common subtype of cancers are expected to drive the uptake of saliva based sampling over the forecast period
Currently, clinical use of isolation and detection technology is limited to CTC quantitation but the number of CTCs is found to hold significant correlation with disease severity. This is, thus, estimated to augment the market over the coming years
Rising awareness regarding advantages of multiple gene analysis along with the help of NGS is anticipated to support the growth of the market
Organizations such as American Society of Clinical Oncology (ASCO) are engaged in supporting implementation of liquid biopsy, which in turn is likely to spur the growth of the market
Intensifying competition between biotech companies and increasing investments by government in healthcare institutes will lead to development of more sophisticated tests
Companies engaged in R&D and commercialization of these products include Pathway Genomics; Natera Inc.; Epic Sciences; Illumina; Foundation Medicine; Roche; LabCorp; and Sequenom
Grand View Research has segmented the global liquid biopsy market on the basis of application, sample type, biomarker, technology, and region:
Liquid Biopsy Application Outlook (Revenue, USD Million, 2013 - 2030)
Therapy Selection for Metastatic Breast Cancer (MBS)
Therapy Selection for Other Metastatic Cancer
Molecular Health Monitoring
Liquid Biopsy Sample Type Outlook (Revenue, USD Million, 2013 - 2030)
Blood Sample based
Urine Sample based
Other Bio Fluids (Tissue fluids and Saliva) based
Liquid Biopsy Biomarker Outlook (Revenue, USD Million, 2013 - 2030)
Circulating Tumor Cells (CTC)
Circulating Tumor DNA (ctDNA)
Liquid Biopsy Technology Outlook (Revenue, USD Million, 2013 - 2030)
Multi-gene-parallel Analysis (NGS)
Single Gene Analysis (PCR Microarrays)
Liquid Biopsy Regional Outlook (Revenue, USD Million, 2013 - 2030)
Explore the BI enabled intuitive market research database,The Grand Library, by Grand View Research, Inc.
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc. Phone: +1-415-349-0058 Toll Free: 1-888-202-9519 Email: firstname.lastname@example.org